Circulating Non-Coding RNAs in Head and Neck Cancer: Roles in Diagnosis, Prognosis, and Therapy Monitoring

Diez-Fraile, Araceli; Ceulaer, Joke De; Derpoorter, Charlotte; Spaas, Christophe; Backer, Tom De; Lamoral, Philippe; Abeloos, Johan; Lammens, Tim

doi:10.3390/cells10010048

Open AccessFeature PaperReview

Circulating Non-Coding RNAs in Head and Neck Cancer: Roles in Diagnosis, Prognosis, and Therapy Monitoring

by

Araceli Diez-Fraile

^1,†,

Joke De Ceulaer

^1,†,

Charlotte Derpoorter

^2,3,4

,

Christophe Spaas

¹,

Tom De Backer

¹,

Philippe Lamoral

¹,

Johan Abeloos

^1,‡ and

Tim Lammens

^2,3,4,*,‡

¹

Division of Oral and Maxillofacial Surgery, Department of Surgery, AZ Sint-Jan Brugge-Oostende A.V., 8000 Bruges, Belgium

²

Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, 9000 Ghent, Belgium

³

Department of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium

⁴

Cancer Research Institute Ghent (C.R.I.G.), 9000 Ghent, Belgium

^*

Author to whom correspondence should be addressed.

^†

Shared first authors.

^‡

Shared senior authors.

Cells 2021, 10(1), 48; https://doi.org/10.3390/cells10010048

Submission received: 21 November 2020 / Revised: 27 December 2020 / Accepted: 28 December 2020 / Published: 31 December 2020

(This article belongs to the Special Issue Circulating RNAs in Health and Disease)

Download

Browse Figures

Versions Notes

Abstract

Head and neck cancer (HNC), the seventh most common form of cancer worldwide, is a group of epithelial malignancies affecting sites in the upper aerodigestive tract. The 5-year overall survival for patients with HNC has stayed around 40–50% for decades, with mortality being attributable mainly to late diagnosis and recurrence. Recently, non-coding RNAs, including tRNA halves, YRNA fragments, microRNAs (miRNAs), and long non-coding RNAs (lncRNAs), have been identified in the blood and saliva of patients diagnosed with HNC. These observations have recently fueled the study of their potential use in early detection, diagnosis, and risk assessment. The present review focuses on recent insights and the potential impact that circulating non-coding RNA evaluation may have on clinical decision-making in the management of HNC.

Keywords: head and neck cancer; circulating non-coding RNA; liquid biopsy; biomarkers

Share and Cite

MDPI and ACS Style

Diez-Fraile, A.; Ceulaer, J.D.; Derpoorter, C.; Spaas, C.; Backer, T.D.; Lamoral, P.; Abeloos, J.; Lammens, T. Circulating Non-Coding RNAs in Head and Neck Cancer: Roles in Diagnosis, Prognosis, and Therapy Monitoring. Cells 2021, 10, 48. https://doi.org/10.3390/cells10010048

AMA Style

Diez-Fraile A, Ceulaer JD, Derpoorter C, Spaas C, Backer TD, Lamoral P, Abeloos J, Lammens T. Circulating Non-Coding RNAs in Head and Neck Cancer: Roles in Diagnosis, Prognosis, and Therapy Monitoring. Cells. 2021; 10(1):48. https://doi.org/10.3390/cells10010048

Chicago/Turabian Style

Diez-Fraile, Araceli, Joke De Ceulaer, Charlotte Derpoorter, Christophe Spaas, Tom De Backer, Philippe Lamoral, Johan Abeloos, and Tim Lammens. 2021. "Circulating Non-Coding RNAs in Head and Neck Cancer: Roles in Diagnosis, Prognosis, and Therapy Monitoring" Cells 10, no. 1: 48. https://doi.org/10.3390/cells10010048

APA Style

Diez-Fraile, A., Ceulaer, J. D., Derpoorter, C., Spaas, C., Backer, T. D., Lamoral, P., Abeloos, J., & Lammens, T. (2021). Circulating Non-Coding RNAs in Head and Neck Cancer: Roles in Diagnosis, Prognosis, and Therapy Monitoring. Cells, 10(1), 48. https://doi.org/10.3390/cells10010048

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Circulating Non-Coding RNAs in Head and Neck Cancer: Roles in Diagnosis, Prognosis, and Therapy Monitoring

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI